Veracyte (NASDAQ:VCYT) vs. Zicix (OTCMKTS:ZICX) Head to Head Analysis

Zicix (OTCMKTS:ZICX) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Zicix and Veracyte, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zicix	0	0	0	0	0.00
Veracyte	1	0	8	0	2.78

Veracyte has a consensus target price of $41.25, indicating a potential upside of 0.36%. Given Veracyte’s stronger consensus rating and higher possible upside, analysts plainly believe Veracyte is more favorable than Zicix.

Risk and Volatility

Zicix has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500.

Profitability

This table compares Zicix and Veracyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zicix	N/A	N/A	N/A
Veracyte	-2.18%	3.02%	2.80%

Earnings and Valuation

This table compares Zicix and Veracyte”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zicix	N/A	N/A	N/A	N/A	N/A
Veracyte	$361.05 million	8.82	-$74.40 million	($0.15)	-274.00

Zicix has higher earnings, but lower revenue than Veracyte.

Summary

Veracyte beats Zicix on 7 of the 8 factors compared between the two stocks.

About Zicix

Zicix Corporation, through its subsidiary, Texas Mobile Health, Inc., provides diagnostic medical imaging services in Houston, Texas. It offers cardiac diagnostic services, including echocardiogram, stress testing, carotid ultrasound, and halter and event monitoring services; medical services, such as general medical care, medical care for home health patients, general and immigration physicals, weight reduction, cold laser pain relief treatment, physical therapy, and anti-aging treatment; and MRI, CT, and X-Ray services. The company was formerly known as Bederra Corporation and changed its name to Zicix Corporation on February 8, 2011. Zicix Corporation was founded in 1979 and is based in Houston, Texas.

About Veracyte

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.